Vigil Neuroscience, Inc. has announced an update regarding its merger with Sanofi. The merger involves Vesper Acquisition Sub Inc., a wholly-owned subsidiary of Sanofi, merging into Vigil Neuroscience, with Vigil continuing as a wholly-owned subsidiary of Sanofi. A key milestone has been reached as the waiting period for the merger has expired as of July 16, 2025. The completion of the merger is still subject to the satisfaction of customary closing conditions, including approval by Vigil's stockholders. A virtual meeting for stockholders to consider the adoption of the merger agreement is scheduled for August 4, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vigil Neuroscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-160213), on July 17, 2025, and is solely responsible for the information contained therein.